Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Lubiniecki, G.M (G. M.)"'
Autor:
Herbst, R.S. (Roy S.), Garon, E.B. (E. B.), Kim, D.W, (D. W.), Chul-Cho, B. (B.), Perez-Gracia, J.L. (Jose Luis), Han, J.Y. (J. Y.), Dubos-Arvis, C. (C.), Majem-Tarruella, M. (Margarita), Forster, M. (M.), Monnet, I. (I.), Novello, S. (S.), Szalai, Z. (Z.), Gubens, M.A. (M. A.), Su, W.C. (W. C.), Ceresoli, G.L. (G. L.), Samkari, A. (A.), Jensen, E.H. (E. H.), Lubiniecki, G.M (G. M.), Baas, P. (P.)
In the global, open-label, phase 2/3 study KEYNOTE-010, pembro 10 mg/kg or 2 mg/kg Q3W improved OS vs docetaxel in pts with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1% (coprimary analyses) at median follow-up of 13.1 mo. We pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1111::0018f024cff23b5ca9b21deafc78bcf7
https://hdl.handle.net/10171/65452
https://hdl.handle.net/10171/65452
